IP Library Granted Patent US 12,186,451
Granted Patent B2
US 12,186,451 · App. 17/251,094 · Granted Jan 7, 2025

Bioartificial vascular pancreas

Inventors: Laura Niklason (Greenwich, CT); Edward Han (Montville, NJ)
Assignee: Yale University
A61L27/3625A61F2/022A61K35/36A61K35/545A61L27/34A61L27/3834A61L27/52A61L27/54A61L2300/43
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,186,451
App. No.
17/251,094
Granted
Jan 7, 2025
Kind
B2
Abstract

The present invention provides compositions, systems and methods for treating diabetes in a subject. The composition of the present invention includes a decellularized vascular graft, a biocompatible hydrogel encasement with tunable rigidity, and a plurality of cells such as pancreatic islet cells.

Claims (13)

1. A composition comprising:

an acellular vascular graft having a lumen that is adapted and configured to be in direct contact with a perfusate passing through it;

a biocompatible hydrogel encasement, wherein the biocompatible hydrogel encasement surrounds an outer surface of the acellular vascular graft; and,

a plurality of cells, wherein the plurality of cells comprises pancreatic islet cells;

wherein the plurality of cells are:

a. seeded on a surface of the biocompatible_hydrogel encasement and/or

b. seeded within the biocompatible hydrogel encasement.

2. The composition of claim 1 , wherein the acellular vascular graft comprises a decellularized arterial graft.

3. The composition of claim 1 , wherein the acellular vascular graft comprises a decellularized venous graft.

4. The composition of claim 1 , wherein the acellular vascular graft comprises a decellularized engineered vascular graft.

5. The composition of claim 1 , wherein the biocompatible hydrogel encasement comprises fibrin, fibrinogen, thrombin, collagen, elastin, gelatin, chitosans, alginate, laminin, hyaluronans, silk, polyethylene glycol, isolated extracellular matrix hydrogels, or combinations thereof.

6. The composition of claim 1 , wherein the plurality of cells are selected from the group consisting of: alpha cells, beta cells, delta cells, PP cells, epsilon cells, insulinoma cells, transgenic cells, knock-out cells, knock-in cells, or otherwise genetically modified cells, embryonic stem cells (ESCs), induced pluripotent stem cells (IPSCs), and combinations thereof.

7. The composition of claim 1 , wherein the pancreatic islet cells are mammalian pancreatic islet cells selected from the group consisting of bovine, porcine, murine, rattus, equine, and human islet cells.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Dec 16, 2025
From: HOOK SA LLC, AS PURCHASER AGENT
To: HUMACYTE GLOBAL, INC.
Reel/Frame 073234/0064 →
SECURITY INTEREST Recorded Dec 15, 2025
From: HUMACYTE, INC.; HUMACYTE GLOBAL, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND II, L.P., AS AGENT
Reel/Frame 073214/0250 →
SECURITY INTEREST Recorded May 15, 2023
From: HUMACYTE GLOBAL, INC.
To: HOOK SA LLC, AS PURCHASER AGENT
Reel/Frame 063638/0933 →
Continuity (2)
Provisional Application 62688141 · Jun 21, 2018
Related Publication 20210128785A1 · May 6, 2021
References Cited (31)
US 4546500A · Bell · 1985 [cited by examiner]
US 5370681A · Herweck · 1994 [cited by examiner]
US 10188499B2 · Winkler et al. · 2019 [cited by applicant]
US 20020142458A1 · Williams et al. · 2002 [cited by applicant]
US 20050209687A1 · Sitzmann · 2005 [cited by examiner]
US 20070254005A1 · Pathak et al. · 2007 [cited by applicant]
US 20110276125A1 · Walker · 2011 [cited by examiner]
US 20140017304A1 · Bosmans et al. · 2014 [cited by applicant]
US 20150094797A1 · Matheny · 2015 [cited by examiner]
US 20150166962A1 · Gerecht et al. · 2015 [cited by applicant]
US 20160030638A1 · Ross · 2016 [cited by applicant]
US 20160058913A1 · Dimitrievska et al. · 2016 [cited by applicant]
US 20160287756A1 · Lewis et al. · 2016 [cited by applicant]
US 20170007391A1 · Inoue · 2017 [cited by applicant]
US 20180085492A1 · Ameer et al. · 2018 [cited by applicant]
US 20200078160A1 · Magin · 2020 [cited by examiner]
CN 103756955A · 2014 [cited by applicant]
CN 103767804A · 2014 [cited by applicant]
CN 106163581A · 2016 [cited by applicant]
EP 3810032A4 · 2022 [cited by applicant]
JP H04292169A · 1992 [cited by applicant]
JP 2014509617A · 2014 [cited by applicant]
JP 2016530899A · 2016 [cited by applicant]
JP 2017018330A · 2017 [cited by applicant]
JP 2018123934A · 2018 [cited by applicant]
WO 2017136786A1 · 2017 [cited by applicant]
WO 2018055452A1 · 2018 [cited by applicant]
WO 2019246416A1 · 2019 [cited by applicant]
International Search Report and Written Opinion for international application No. PCT/US2019/038277, issued on Oct. 2, 2019. [cited by applicant]
Lin, et al. “In vivo performance of decellularized vascular grafts: a review article.” International journal of molecular sciences 19.7 (2018): 2101. [cited by applicant]
Extended European Search Report for European Application No. 19822304.2, issued on Mar. 7, 2022. [cited by applicant]